Skip to Main Content

++

INTRODUCTION

++

cefditoren (sef-di-tore-en)

Spectracef

Classification

Therapeutic: anti-infectives

Pharmacologic: third-generation cephalosporins

++
Indications
++

Treatment of the following infections caused by susceptible organisms: Acute exacerbations of chronic bronchitis, Community-acquired pneumonia, Pharyngitis and tonsillitis, Uncomplicated skin and skin structure infections.

++
Action
++

Binds to bacterial cell wall membrane, causing cell death. Therapeutic Effects: Bactericidal action against susceptible bacteria. Spectrum: Active against the following gram-positive organisms: Staphylococcus aureus (methicillin-susceptible strains, including β-lactamase–producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), Str. pyogenes. Active against the following gram-negative organisms: Haemophilus influenzae (including β-lactamase–producing strains), H. parainfluenzae (including β-lactamase–producing strains), Moraxella catarrhalis (including β-lactamase–producing strains).

++
Adverse Reactions/Side Effects
++

CNS: SEIZURES (HIGH DOSES), headache. GI: PSEUDOMEMBRANOUS COLITIS, diarrhea, abdominal pain, dyspepsia, nausea, vomiting. GU: hematuria, vaginal moniliasis. Hemat: bleeding, eosinophilia, hemolytic anemia, lymphocytosis, neutropenia, thrombocytosis. Misc: allergic reactions. including anaphylaxis, superinfection.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Watch for seizures; notify physician immediately if patient develops or increases seizure activity.

  • Monitor signs of pseudomembranous colitis, including diarrhea, abdominal pain, fever, pus or mucus in stools, and other severe or prolonged GI problems (nausea, vomiting, heartburn). Notify physician or nursing staff immediately of these signs.

  • Monitor signs of allergic reactions and anaphylaxis, including pulmonary symptoms (tightness in the throat and chest, wheezing, cough dyspnea) or skin reactions (rash, pruritus, urticaria). Notify physician or nursing staff immediately if these reactions occur.

  • Monitor signs of blood dyscrasias, including eosinophilia (fatigue, weakness, myalgia), hemolytic anemia (malaise, dizziness, jaundice, abdominal pain), neutropenia (fever, sore throat, mucosal lesions, signs of infection), and thrombocytopenia (bruising, nose bleeds, bleeding gums, other unusual bleeding). Report these signs to the physician.

  • Assess dizziness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician and nursing staff, and caution the patient and family/caregivers to guard against falls and trauma.

++
Interventions
++

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Use universal precautions or isolation procedures as indicated for specific patients.

++
Patient/Client-Related Instruction
++

  • Instruct patient to notify physician immediately of signs of superinfection, including black, furry overgrowth on tongue, vaginal itching or discharge, and loose or foul-smelling stools.

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged headache, skin problems (rash, hives), vaginal infections, blood in the urine, or GI problems (nausea, vomiting, diarrhea, abdominal pain, heartburn).

++
Pharmacokinetics
++

Absorption: Cefditoren pivoxil is a prodrug that is converted to cefditoren (the active component) in GI tract during absorption. Bioavailability 14% in fasting state, increased by high fat meal.

++

Distribution: Widely distributed.

++

...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.